Zacks Bull and Bear of the Day Highlights: Maxim Integrated, BJ’s ...
Business Wire (press release) - San Francisco,CA,USA
We are downgrading our rating on Acorda Therapeutics (Nasdaq: ACOR) form Hold to Sell. Recent positive phase III data on Fampridine-SR drove the stock up ...

Third Point Calls for Board to Sell Acorda Therapeutics, Inc.
Yahoo! News (press release) - USA
On September 25, 2006, the Company announced statistically significant results from the PIII study of Fampridine-SR for walking improvement in multiple ...
See all stories on this topic

Acorda Therapeutics "buy," target price raised
newratings.com - USA
The SPA for the second Phase III trial of Fampridine-SR in MS is coming close to completion, with trial initiation expected in 2Q07 and completion ...
See all stories on this topic

Analyst initiations 2-21-07: Coach & Avaya initiated today
Blogging Stocks - USA
Morgan Joseph started Acorda Therapeutics Inc (NASDAQ: ACOR) with a Sell rating and $15 target citing seizure rates for Fampridine-SR and limited efficacy ...